Drug Profile
EPX 300
Alternative Names: EPX-300Latest Information Update: 07 Sep 2022
Price :
$50
*
At a glance
- Originator Epygenix Therapeutics
- Class Antidepressants; Antiepileptic drugs
- Mechanism of Action Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Dravet syndrome; Lennox-Gastaut syndrome
Most Recent Events
- 07 Sep 2022 Phase-II clinical trials in Lennox-Gastaut syndrome in USA (unspecified route) prior to September 2022 (Epygenix Therapeutics pipeline, September 2022)
- 18 Jul 2022 Epygenix Therapeutics announces intention to submit an IND application with the regulatory bodies for Dravet syndrome (Epygenix Therapeutics pipeline, July 2022)
- 05 Oct 2020 EPX 300 is still in phase II development for Dravet syndrome in USA (Epygenix Therapeutics pipeline, October 2020)